Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR.

JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.

PMID:
30735235
2.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L.

Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.

PMID:
25656287
3.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L.

Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9.

PMID:
26968359
4.

Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.

Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D.

Cureus. 2015 Dec 4;7(12):e395. doi: 10.7759/cureus.395.

5.

Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].

LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep.

6.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

7.

Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design.

Ward MC, Ross RB, Koyfman SA, Lorenz R, Lamarre ED, Scharpf J, Burkey BB, Joshi NP, Woody NM, Prendes B, Houston N, Reddy CA, Greskovich JF, Adelstein DJ.

JAMA Otolaryngol Head Neck Surg. 2016 Dec 1;142(12):1164-1170. doi: 10.1001/jamaoto.2016.1876.

PMID:
27438230
8.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.

PMID:
30579763
9.

Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.

Boyer MJ, Papagikos MA, Kiteley R, Vujaskovic Z, Wu J, Lee WR.

Radiat Oncol. 2017 Jan 13;12(1):14. doi: 10.1186/s13014-016-0758-8.

10.

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma.

Kim HJ, Phak JH, Kim WC.

Radiat Oncol J. 2016 Dec;34(4):260-264. doi: 10.3857/roj.2015.01571. Epub 2016 Jun 17.

11.

Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.

Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e795-801. doi: 10.1016/j.ijrobp.2011.11.040. Epub 2012 Feb 11.

PMID:
22330999
12.

High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.

Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, Park SJ, Marks L, Pantuck A, Steinberg M, Kamrava M.

Brachytherapy. 2017 Mar - Apr;16(2):299-305. doi: 10.1016/j.brachy.2016.11.002. Epub 2016 Dec 10.

PMID:
27965117
14.

Stereotactic Body Radiotherapy for Primary Prostate Cancer.

Kothari G, Loblaw A, Tree AC, van As NJ, Moghanaki D, Lo SS, Ost P, Siva S.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789633. doi: 10.1177/1533033818789633.

15.

Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.

Berlin A, Cho E, Kong V, Howell KJ, Lao B, Craig T, Bayley A, Chung P, Gospodarowicz M, Warde P, Catton C, Bristow RG, Ménard C.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):e473-e482. doi: 10.1016/j.prro.2015.02.015. Epub 2015 Apr 18.

PMID:
25899220
16.

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H.

JAMA Oncol. 2018 Jun 14;4(6):e180039. doi: 10.1001/jamaoncol.2018.0039. Epub 2018 Jun 14.

17.

Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.

Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DWN, Pistenmaa D, Lotan Y, Timmerman R.

Eur J Cancer. 2016 May;59:142-151. doi: 10.1016/j.ejca.2016.02.014. Epub 2016 Mar 29.

PMID:
27035363
18.

Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.

Kotecha R, Djemil T, Tendulkar RD, Reddy CA, Thousand RA, Vassil A, Stovsky M, Berglund RK, Klein EA, Stephans KL.

Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):960-964. doi: 10.1016/j.ijrobp.2016.02.009. Epub 2016 Feb 6.

PMID:
27302511
19.

High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients.

D'Agostino G, Franzese C, De Rose F, Franceschini D, Comito T, Villa E, Alongi F, Liardo R, Tomatis S, Navarria P, Mancosu P, Reggiori G, Cozzi L, Scorsetti M.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):e173-e178. doi: 10.1016/j.clon.2016.06.013. Epub 2016 Jul 4.

PMID:
27389021
20.

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodríguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villà S, Perez de la Haza A, Calvo FA.

Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 19. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25702876

Supplemental Content

Support Center